AI
Wednesday, September 21, 2016 1:10:34 PM
CEO Steve King Tomorrow/9-22-16 Panelist in Berlin w/BMS/Merck/Agenus at Phacilitate’s “Immunotherapy Europe (Strategic Partnering Event)”. At 1st I thought it was a webinar, but the Webinar/Signup button only shows a 9-2-16 webcast on Immunotherapy.
Sept21-22 2016: “Phacilitate’s Immunotherapy Europe (Strategic Partnering Event)” Berlin, GER
“The Perfect Combination of Strategy & Innovation - Advancing immuno-oncology business & R&D models at Europe’s inaugural strategic partnering event. Delivering combination therapy, biomarkers, imaging, pricing & reimbursement, R&D and supply chain models to ensure next-generation immuno-oncology success.”
http://www.cgteurope.com/page.cfm/action=Seminar/libID=1/libEntryID=47
**PHACILITATE is a specialist in the organization of exclusive events for leaders from the pharma & biotech communities. Our philosophy is simple - to deliver the ultimate in strategic knowledge exchange & networking through flawless, personalized service.
Brochure: http://www.cgteurope.com/files/immunotherapy_europe_final_announcement.pdf
9-22-16 9:50-10:20am Panel:
“Analyzing The Business & Partnering Model In Industry & Academia For The Future Development Of Immuno-Oncology Combination Therapies”
Panelists/Speakers:
* Donnie McGrath - VP, Head Search & Evaluation, BusDev, Bristol-Myers Squibb
* Emmett Schmidt = Exec.Dir., Clinical Research, Merck Sharp & Dohme
* Jennifer Buell VP, Development Operations, Agenus
* Steven King – Pres. & CEO, Peregrine Pharmaceuticals - http://www.cgteurope.com/page.cfm/Action=Visitor/VisitorID=139
.
= = = = = = = = = = =KNOWN UPCOMING (updated):
Sep22: Phacilitate’s "Immunotherapy Europe" (Strategic Partnering Event), Berlin http://tinyurl.com/hwxax88
...9:50-10:20am WEBINAR - CEO Steve King is Panelist w/BMS/Merck/Agenus: “Analyzing The Business & Partnering Model in Industry & Academia for the Future Dev. of I-O Combination Therapies”
Sep25-28: 2nd AACR-CRI Intl. Cancer Immunotherapy Conf.”, NYC http://tinyurl.com/hj3ar5q
...Sep26 5:15-7:45pm: Bruce Freimark(Dir.Res/Preclin.Oncology) poster B019, “LAG3 is an Immunotherapeutic Target in Murine Triple- Breast Cancers, Whose Activity is Significantly Enhanced in Combo with PS-Targeting Antibodies”
...Sep26 5:15-7:45pm: Dr. Raymond Birge**(Rutgers) & PPHM poster B119, ”Characterization of a PS, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer”
**Dr. Raymond Birge has authored ~85 scientific publications in molecular & cancer biology. “The Birge laboratory conducts basic science focused on the eradication of cancer.” http://birgelab.org
Oct4-7/Avid/Booth#716: IBC's BioProcess Intl. Conf., Boston http://www.ibclifesciences.com/BPI/overview.xml & http://tinyurl.com/zyblds7
...10-5-16/8-8:30am: Peter Gagnon(Avid's VP/Process-Svcs), ”Across the Great Divide: The Upstream Origins & Downstream Ramifications of a Newly Discovered Contaminant Class”
Oct7-11: 41st ESMO European Cancer Congress, Copenhagen, Denmark http://tinyurl.com/j7ud5an (Oral Pres. of Topline Data from Ph3 SUNRISE trial, incl. initial Biomarker analysis)
...10-10-16 9:15-9:30am: David R. Spigel (CSO/Dir./Sarah Cannon Res. Inst., Nashville) Proffered Oral Presentation, “Top-line Results from Ph3/SUNRISE..." (Senior-Author: David Gerber/UTSW)
......9-21-16 PR said, "Presented data will include a biomarker in the SUNRISE trial that correlated with a statistically significant improvement in OS for patients treated with Bavi+Doce vs. Doce alone.”
...10-9-16 1:00-2:00pm: Jeff Hutchins(VP/PreClin.Res), “Antibody Mediated Blockade of PS Improves Immune Checkpoint Blockade...”
Oct13/10am: Annual SHM, Avenue of the Arts Hotel, Costa Mesa – Final Proxy: http://tinyurl.com/gsrmgs2
Nov9-13: (SITC) Society for Immunotherapy of Cancer 31st Annual Meeting”, Natl-Harbor MD http://www.sitcancer.org/2016
...”First Results” from our collaboration with Jedd Wolchok Lab investigators (MSK) to be presented” (per 9-8-16/Ccall/Hutchins)
~Dec8: FY'17Q2 (qe 10-31-16) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid/Booth#209: IBC's Antibody Eng. & Therapeutics 2016”, SanDiego http://www.ibclifesciences.com/AntibodyEng/overview.xml
Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & I-O”, SanFran http://www.triconference.com/Pre-Clinical-Oncology-Models
...Bruce Freimark(Dir.Res/Preclin.Oncology), ”Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
Sept21-22 2016: “Phacilitate’s Immunotherapy Europe (Strategic Partnering Event)” Berlin, GER
“The Perfect Combination of Strategy & Innovation - Advancing immuno-oncology business & R&D models at Europe’s inaugural strategic partnering event. Delivering combination therapy, biomarkers, imaging, pricing & reimbursement, R&D and supply chain models to ensure next-generation immuno-oncology success.”
http://www.cgteurope.com/page.cfm/action=Seminar/libID=1/libEntryID=47
**PHACILITATE is a specialist in the organization of exclusive events for leaders from the pharma & biotech communities. Our philosophy is simple - to deliver the ultimate in strategic knowledge exchange & networking through flawless, personalized service.
Brochure: http://www.cgteurope.com/files/immunotherapy_europe_final_announcement.pdf
9-22-16 9:50-10:20am Panel:
“Analyzing The Business & Partnering Model In Industry & Academia For The Future Development Of Immuno-Oncology Combination Therapies”
Panelists/Speakers:
* Donnie McGrath - VP, Head Search & Evaluation, BusDev, Bristol-Myers Squibb
* Emmett Schmidt = Exec.Dir., Clinical Research, Merck Sharp & Dohme
* Jennifer Buell VP, Development Operations, Agenus
* Steven King – Pres. & CEO, Peregrine Pharmaceuticals - http://www.cgteurope.com/page.cfm/Action=Visitor/VisitorID=139
.
= = = = = = = = = = =KNOWN UPCOMING (updated):
Sep22: Phacilitate’s "Immunotherapy Europe" (Strategic Partnering Event), Berlin http://tinyurl.com/hwxax88
...9:50-10:20am WEBINAR - CEO Steve King is Panelist w/BMS/Merck/Agenus: “Analyzing The Business & Partnering Model in Industry & Academia for the Future Dev. of I-O Combination Therapies”
Sep25-28: 2nd AACR-CRI Intl. Cancer Immunotherapy Conf.”, NYC http://tinyurl.com/hj3ar5q
...Sep26 5:15-7:45pm: Bruce Freimark(Dir.Res/Preclin.Oncology) poster B019, “LAG3 is an Immunotherapeutic Target in Murine Triple- Breast Cancers, Whose Activity is Significantly Enhanced in Combo with PS-Targeting Antibodies”
...Sep26 5:15-7:45pm: Dr. Raymond Birge**(Rutgers) & PPHM poster B119, ”Characterization of a PS, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer”
**Dr. Raymond Birge has authored ~85 scientific publications in molecular & cancer biology. “The Birge laboratory conducts basic science focused on the eradication of cancer.” http://birgelab.org
Oct4-7/Avid/Booth#716: IBC's BioProcess Intl. Conf., Boston http://www.ibclifesciences.com/BPI/overview.xml & http://tinyurl.com/zyblds7
...10-5-16/8-8:30am: Peter Gagnon(Avid's VP/Process-Svcs), ”Across the Great Divide: The Upstream Origins & Downstream Ramifications of a Newly Discovered Contaminant Class”
Oct7-11: 41st ESMO European Cancer Congress, Copenhagen, Denmark http://tinyurl.com/j7ud5an (Oral Pres. of Topline Data from Ph3 SUNRISE trial, incl. initial Biomarker analysis)
...10-10-16 9:15-9:30am: David R. Spigel (CSO/Dir./Sarah Cannon Res. Inst., Nashville) Proffered Oral Presentation, “Top-line Results from Ph3/SUNRISE..." (Senior-Author: David Gerber/UTSW)
......9-21-16 PR said, "Presented data will include a biomarker in the SUNRISE trial that correlated with a statistically significant improvement in OS for patients treated with Bavi+Doce vs. Doce alone.”
...10-9-16 1:00-2:00pm: Jeff Hutchins(VP/PreClin.Res), “Antibody Mediated Blockade of PS Improves Immune Checkpoint Blockade...”
Oct13/10am: Annual SHM, Avenue of the Arts Hotel, Costa Mesa – Final Proxy: http://tinyurl.com/gsrmgs2
Nov9-13: (SITC) Society for Immunotherapy of Cancer 31st Annual Meeting”, Natl-Harbor MD http://www.sitcancer.org/2016
...”First Results” from our collaboration with Jedd Wolchok Lab investigators (MSK) to be presented” (per 9-8-16/Ccall/Hutchins)
~Dec8: FY'17Q2 (qe 10-31-16) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid/Booth#209: IBC's Antibody Eng. & Therapeutics 2016”, SanDiego http://www.ibclifesciences.com/AntibodyEng/overview.xml
Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & I-O”, SanFran http://www.triconference.com/Pre-Clinical-Oncology-Models
...Bruce Freimark(Dir.Res/Preclin.Oncology), ”Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
